Aurora-B and HDAC synergistically regulate survival and proliferation of lymphoma cell via AKT, mTOR and Notch pathways.
about
Aurora kinases: novel therapy targets in cancersInfluence of a novel histone deacetylase inhibitor panobinostat (LBH589) on the growth of ovarian cancer.Safety, pharmacokinetics, and antitumor properties of anlotinib, an oral multi-target tyrosine kinase inhibitor, in patients with advanced refractory solid tumorsAntitumor effects of anlotinib in thyroid cancer
P2860
Aurora-B and HDAC synergistically regulate survival and proliferation of lymphoma cell via AKT, mTOR and Notch pathways.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年学术文章
@wuu
2015年学术文章
@zh
2015年学术文章
@zh-cn
2015年学术文章
@zh-hans
2015年学术文章
@zh-my
2015年学术文章
@zh-sg
2015年學術文章
@yue
2015年學術文章
@zh-hant
name
Aurora-B and HDAC synergistica ...... AKT, mTOR and Notch pathways.
@en
Aurora-B and HDAC synergistica ...... AKT, mTOR and Notch pathways.
@nl
type
label
Aurora-B and HDAC synergistica ...... AKT, mTOR and Notch pathways.
@en
Aurora-B and HDAC synergistica ...... AKT, mTOR and Notch pathways.
@nl
prefLabel
Aurora-B and HDAC synergistica ...... AKT, mTOR and Notch pathways.
@en
Aurora-B and HDAC synergistica ...... AKT, mTOR and Notch pathways.
@nl
P2093
P1476
Aurora-B and HDAC synergistica ...... AKT, mTOR and Notch pathways.
@en
P2093
P356
10.1016/J.EJPHAR.2015.11.049
P407
P577
2015-11-27T00:00:00Z